St Louis, MO Clinical Trials Report — April 2026

For St. Louis residents considering participation in clinical research, April 2026 presents a critical window for those looking to join studies before enrollment concludes. Across St. Louis, 77 clinical trials are slated to close within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 9 of these rapidly closing studies are still actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly.

Impending Deadlines for Specific Conditions

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on neurological conditions, various cancers, and metabolic health are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Alzheimer disease (4 trials)
• Stage IV lung cancer AJCC V8 (2 trials)
• Heart failure (2 trials)
• Metastatic undifferentiated pleomorphic sarcoma (2 trials)
• Unresectable dedifferentiated liposarcoma (2 trials)
• Unresectable undifferentiated pleomorphic sarcoma (2 trials)
• Obesity (2 trials)
• Deep venous thrombosis (2 trials)
• Metastatic dedifferentiated liposarcoma (2 trials)
• Metastatic malignant solid neoplasm (2 trials)

This month, St. Louis saw the opening of 13 new clinical trials, matching the number of trials that launched in March 2026. Despite this consistent pace, the city remains a significant hub for medical research, with a total of 1,338 clinical trials currently recruiting across 419 research facilities.

Spotlight on New Research Opportunities

April brings several high-profile new trials to St. Louis, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Memorial Sloan Kettering Cancer Center is sponsoring NCT07507643, "A Study of Methylprednisolone in People Having Liver Surgery." This Phase 3 study, aiming for 750 participants, investigates whether methylprednisolone administered before surgery can reduce side effects like infections and shorten hospital stays.
• Kinaset Therapeutics Inc is launching NCT07532265, "A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma." This Phase 2 dose-ranging study seeks 512 participants to evaluate the efficacy and safety of Frevecitinib over a 12-week treatment period in patients with severe asthma not controlled with standard therapy.
• Carelon Research is leading NCT07525843, "A Pragmatic Clinical Trial of the WE BEAT Well-Being Education Program in Adolescent Congenital Heart Disease: WE BEAT CHD Study." This study, involving 390 participants, aims to determine if the WE BEAT program, a 5-week online wellbeing and skill-building program, can help teens with congenital heart disease improve their ability to handle stress.
• Boehringer Ingelheim is initiating NCT07544654, "A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy." This Phase 3 study is open to adults with advanced extrapulmonary neuroendocrine cancer and seeks to find out if obrixtamig plus standard chemotherapy improves survival compared to standard chemotherapy alone for 390 participants.
• The AIDS Malignancy Consortium is sponsoring NCT07539454, "Nirogacestat in Patients With Kaposi Sarcoma." This Phase 2 trial studies how well nirogacestat works in treating patients with skin Kaposi sarcoma, aiming for 28 participants.

New trials this month are exploring a range of conditions, including adolescent congenital heart disease, aging, AIDS-related Kaposi sarcoma, breast cancer, COVID-19, heart failure (diastolic and systolic), and hepatectomy. Drug trials account for the majority of new studies, with 6 new drug trials, followed by 2 behavioral trials, 2 device trials, and 2 procedure trials. Academic institutions, particularly Washington University School of Medicine, are prominent sponsors, alongside industry leaders like Boehringer Ingelheim, Eli Lilly and Company, and Kinaset Therapeutics Inc.

For individuals without a specific medical condition, there are significant opportunities to contribute. 3 of the new trials launched this month are actively seeking healthy volunteers. Across St. Louis, a total of 113 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

St. Louis's Research Hubs

St. Louis is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Washington University School of Medicine (424 trials)
• Washington University (131 trials)
• Mercy Hospital Saint Louis (95 trials)
• Mercy Hospital South (83 trials)
• Siteman Cancer Center-South County (83 trials)
• Missouri Baptist Medical Center (78 trials)
• Siteman Cancer Center at Christian Hospital (77 trials)
• Washington University in St. Louis (68 trials)
• Research Site (47 trials)
• Mercy Infusion Center - Chippewa (27 trials)
• Washington University School of Medicine in St. Louis (27 trials)
• Cardinal Glennon Children's Medical Center (24 trials)

These institutions offer a broad spectrum of research, from oncology at the Siteman Cancer Centers to diverse medical fields at Washington University's various campuses and the Mercy Hospital network.

Broadening Your Search: Nearby Options

While St. Louis offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Missouri. Cities with active trials include Saint Charles (3 trials), Kansas City (2 trials), Columbia (1 trial), and Springfield (1 trial).

Participation in clinical trials is open to a diverse range of individuals. Of the 13 new trials launched this month, 11 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 1 new trial is specifically designed for female participants, and 1 includes children. Academic institutions, particularly Washington University School of Medicine, continue to play a vital role in St. Louis's research ecosystem, sponsoring the majority of new trials this month.

As we move further into spring, the focus will remain on the ongoing enrollment in these significant Phase 2 and 3 trials and the continued exploration of new therapeutic strategies, with St. Louis's robust research community at the forefront of medical innovation.